Business Wire

CA-VISA-INC.

Share
Visa Champions a New Decade for Women’s Empowerment

Kicking off Women’s History Month, Visa (NYSE:V) today announced two new partnerships bolstering the company’s commitment to women’s economic empowerment. Hand In Hand International and IFundWomen will join Visa to help provide both educational resources and funding for women entrepreneurs around the globe to help them build and grow their businesses. The global rate of female entrepreneurship has been increasing more quickly than that of male entrepreneurs1 , with more than 250 million women around the world engaged in entrepreneurship2 .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200303005388/en/

“Women power economies around the world and increasingly are a driving force in the creation of new businesses,” said Al Kelly, chief executive officer and chairman, Visa. “Visa is committed to using the full power of our network, brand and financial resources to put a spotlight on this growing economic force and help female entrepreneurs achieve their dreams.”

About the Partnerships:

  • IFundWomen : IFundWomen is a funding and education platform that provides access to capital through grants and crowdfunding, expert business coaching and a network of women business owners. Visa’s new global partnership with IFundWomen is specifically designed to help entrepreneurs secure the funding they need through a series of grant contests. To find out more and apply for a grant, entrepreneurs can visit IFundWomen.com/Visa .
  • Hand in Hand International: As part of the company’s mission to enable individuals, businesses and economies to thrive, Visa is launching a $2.4 million, three-year partnership with Hand in Hand International, a global non-profit organization that focuses on developing economies in Africa, South Asia and the Middle East. Visa’s partnership with Hand in Hand International will focus on providing business education and broadened financial services access to 10,000 micro businesses in Kenya – at least 75% of which are owned by women. The partnership will further women’s economic empowerment, which has a multiplier effect3 , boosting economic growth and leading to greater development outcomes.

In conjunction with the partnerships, Visa today unveiled initial findings from the second annual “State of Female Entrepreneurship” report4 . The annual study seeks to understand the goals, aspirations and challenges facing women business owners today. Key findings included that funding remains a top challenge: 79% of women entrepreneurs in the United States feel more empowered now than they did five years ago, yet 66% report difficulty in obtaining the funding they need.

“In an increasingly digital world, businesses need to constantly adapt to shifting consumer preferences. But keeping up is challenging, especially for a small business. The women entrepreneurs I have met echo a need for more access to capital to fund, run and grow their businesses,“ said Suzan Kereere, global head of merchant sales and acquiring, Visa. “We are excited to help level the playing field through more access to tools and grants this year, and will continue to champion women in all facets of life in the pursuit of an inclusive digital society.”

Visa has demonstrated a longstanding commitment to empower women through partnerships, programs and sponsorships. The company’s more recent efforts include:

  • Women in Business:
    • Female Founder Collective: Visa has entered its second year of partnership with Rebecca Minkoff’s Female Founder Collective . To kickoff, Visa will host a workshop at Female Founders Day , where a diverse mix of lending and digital payment experts will discuss strategies small business can use for loans and capital.
    • Women’s World Banking: In 2017, the Visa Foundation made their inaugural grant of $20 million to Women’s World Banking to help women-led micro and small business owners increase access to capital and to help grow their businesses. The program is on track to reach 1 million women by the end of the year.
    • She’s Next, Empowered by Visa: In 2019, Visa launched its women-owned small business initiative, She’s Next, Empowered by Visa , with workshops in New York, Atlanta, Toronto and Cape Town at the World Economic Forum in South Africa. She’s Next leverages Visa’s brand and network to empower women entrepreneurs with tools to build their businesses, ultimately creating a ripple effect throughout their communities.
  • Women in Sport:
    • The SheBelieves Cup: As the sponsor of the SheBelieves Cup, Visa will present the first-ever MVP trophy to the most inspiring and empowering athlete on the field during the tournament, selected by a committee of former female footballers. Visa will also host a Practical Money Skills workshop at the SheBelieves Summit, which underscores the importance of financial literacy and how to plan ahead for financial success.
    • The Second Half: Inspired by Visa’s groundbreaking partnership with UEFA Women’s Football and the FIFA Women’s World CupTM , Visa recently announced the launch of The Second Half ; a career development program to support female footballers in Europe, as they consider their careers beyond the football pitch.
    • Olympic and Paralympic Games: Visa’s sponsored athlete program of Olympic and Paralympic hopefuls, Team Visa, has been comprised of more than 50% women athletes looking back historically at the full roster. For Tokyo 2020, Visa is supporting more than 50 female Olympic and Paralympic hopefuls from around the world. Additionally, in the lead up to the Olympic Winter Games Beijing 2022 - Visa, the China Women’s Development Foundation and Beijing Sport University announced a program aimed to empower women to grow their small businesses and contribute to local social-economic development and sustainable growth.

About Visa Inc.

Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device, for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa , visa.com/blog and @VisaNews .

1 Gem 2016/2017 Women's Entrepreneurship Report
2 Gem 2018/2019 Women's Entrepreneurship Report
3 International Monetary Fund’s Pursuing Women's Economic Empowerment
4 Visa 2020 State of Female Entrepreneurship Report, conducted by Logica Research on behalf of Visa to 400 adult, female small business owners in February 2020

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye